Smart Sense Childrens Allergy Relief label

Smart Sense Childrens Allergy Relief

Smart Sense Childrens Allergy Relief Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

Do not use

•
with any other product containing diphenhydramine, even one used on skin
•
to make a child sleepy

Ask a doctor before use if the child has

•
a breathing problem such as chronic bronchitis
•
glaucoma
•
a sodium-restricted diet

Ask a doctor or pharmacist before use if the child is

taking sedatives or tranquilizers

When using this product

•
marked drowsiness may occur
•
excitability may occur, especially in children
•
sedatives and tranquilizers may increase drowsiness

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)

Do not use

•
with any other product containing diphenhydramine, even one used on skin
•
to make a child sleepy

Ask a doctor before use if the child has

•
a breathing problem such as chronic bronchitis
•
glaucoma
•
a sodium-restricted diet

Ask a doctor or pharmacist before use if the child is

taking sedatives or tranquilizers

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

•
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies:
•
sneezing
•
itching of the nose or throat
•
runny nose
•
itchy, watery eyes

History

There is currently no drug history available for this drug.

Other Information

There are no additional details available for this product.

Smart Sense Childrens Allergy Relief Manufacturers

  • Smart Sense Childrens Allergy Relief | Pd-rx Pharmaceuticals, Inc.
    No Recall

    Smart Sense Childrens Allergy Relief | Pd-rx Pharmaceuticals, Inc.

    Smart Sense Childrens Allergy Relief | Pd-rx Pharmaceuticals, Inc.
    Hypertension

    The dosage of metoprolol tartrate should be individualized. Metoprolol tartrate should be taken with or immediately following meals.

    The usual initial dosage is 100 mg daily in single or divided doses, whether used alone or added to a diuretic. The dosage may be increased at weekly (or longer) intervals until optimum blood pressure reduction is achieved. In general, the maximum effect of any given dosage level will be apparent after 1 week of therapy. The effective dosage range is 100 mg to 450 mg per day. Dosages above 450 mg per day have not been studied. While once-daily dosing is effective and can maintain a reduction in blood pressure throughout the day, lower doses (especially 100 mg) may not maintain a full effect at the end of the 24-hour period, and larger or more frequent daily doses may be required. This can be evaluated by measuring blood pressure near the end of the dosing interval to determine whether satisfactory control is being maintained throughout the day. Beta 1 selectivity diminishes as the dose of metoprolol tartrate is increased.

    Angina Pectoris

    The dosage of metoprolol tartrate should be individualized. Metoprolol tartrate should be taken with or immediately following meals.

    The usual initial dosage is 100 mg daily, given in two divided doses. The dosage may be gradually increased at weekly intervals until optimum clinical response has been obtained or there is pronounced slowing of the heart rate. The effective dosage range is 100 mg to 400 mg per day. Dosages above 400 mg per day have not been studied. If treatment is to be discontinued, the dosage should be reduced gradually over a period of 1-2 weeks. (See WARNINGS.)

    Myocardial Infarction Early Treatment:

    During the early phase of definite or suspected acute myocardial infarction, treatment with metoprolol can be initiated as soon as possible after the patient’s arrival in the hospital. Such treatment should be initiated in a coronary care or similar unit immediately after the patient’s hemodynamic condition has stabilized.

    Treatment in this early phase should begin with the intravenous administration of three bolus injections of 5 mg of metoprolol tartrate each; the injections should be given at approximately 2-minute intervals. During the intravenous administration of metoprolol, blood pressure, heart rate, and electrocardiogram should be carefully monitored.

    In patients who tolerate the full intravenous dose (15 mg), metoprolol tartrate tablets, 50 mg every 6 hours, should be initiated 15 minutes after the last intravenous dose and continued for 48 hours. Thereafter, patients should receive a maintenance dosage of 100 mg twice daily (see Late Treatment below).

    Patients who appear not to tolerate the full intravenous dose should be started on metoprolol tartrate tablets either 25 mg or 50 mg every 6 hours (depending on the degree of intolerance) 15 minutes after the last intravenous dose or as soon as their clinical condition allows.

    In patients with severe intolerance, treatment with metoprolol should be discontinued (see WARNINGS).

    Late Treatment

    Patients with contraindications to treatment during the early phase of suspected or definite myocardial infarction, patients who appear not to tolerate the full early treatment, and patients in whom the physician wishes to delay therapy for any other reason should be started on metoprolol tartrate tablets, 100 mg twice daily, as soon as their clinical condition allows. Therapy should be continued for at least 3 months. Although the efficacy of metoprolol beyond 3 months has not been conclusively established, data from studies with other beta blockers suggest that treatment should be continued for 1 to 3 years.